Condition: Amyotrophic Lateral Sclerosis · Sponsor: Ractigen Therapeutics.
This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects with Amyotrophic Lateral Sclerosis (ALS) with Superoxide Dismutase Type 1 (SOD1) Gene Mutation
This description comes directly from the study's public registry record.
Long-Cheng Li · +86 18051622388 · lilc@ractigen.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital | Beijing, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, China | Recruiting |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06556394